Ascendis Pharma A/S (ASND) Projected to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($1.56) per share and revenue of $98.56 million for the quarter.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Trading Up 0.4 %

Shares of ASND opened at $164.88 on Tuesday. The stock has a market cap of $10.05 billion, a P/E ratio of -23.22 and a beta of 0.54. The company has a 50-day moving average of $153.97 and a two-hundred day moving average of $139.28. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ASND shares. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Cantor Fitzgerald lifted their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, February 25th. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, March 18th. Finally, Royal Bank of Canada initiated coverage on shares of Ascendis Pharma A/S in a report on Wednesday, April 16th. They set an “outperform” rating and a $205.00 price target for the company. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $204.67.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.